Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 3
1979 2
1981 1
1983 1
1984 1
1985 3
1987 1
1989 1
1990 2
1991 3
1992 1
1993 1
1994 1
1995 2
1996 4
1997 1
1999 1
2000 3
2001 6
2002 3
2003 6
2004 1
2005 2
2006 3
2007 1
2008 2
2009 2
2010 4
2011 5
2012 2
2013 1
2014 2
2016 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. Among authors: lacave aj. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG. Pfisterer J, et al. Among authors: lacave aj. J Clin Oncol. 2006 Oct 10;24(29):4699-707. doi: 10.1200/JCO.2006.06.0913. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966687 Clinical Trial.
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Viéitez JM, Valladares M, Peláez I, de Sande González L, García-Foncillas J, García-López JL, García-Girón C, Reboredo M, Bovio H, Lacave AJ. Viéitez JM, et al. Among authors: lacave aj. Invest New Drugs. 2011 Oct;29(5):1038-44. doi: 10.1007/s10637-010-9400-z. Epub 2010 Mar 6. Invest New Drugs. 2011. PMID: 20204674 Clinical Trial.
Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications.
sbv IMPROVER project team and challenge best performers; Namasivayam AA, Morales AF, Lacave ÁM, Tallam A, Simovic B, Alfaro DG, Bobbili DR, Martin F, Androsova G, Shvydchenko I, Park J, Calvo JV, Hoeng J, Peitsch MC, Racero MG, Biryukov M, Talikka M, Pérez MB, Rohatgi N, Díaz-Díaz N, Mandarapu R, Ruiz RA, Davidyan S, Narayanasamy S, Boué S, Guryanova S, Arbas SM, Menon S, Xiang Y. sbv IMPROVER project team and challenge best performers, et al. Among authors: lacave am. Gene Regul Syst Bio. 2016 Jul 12;10:51-66. doi: 10.4137/GRSB.S39076. eCollection 2016. Gene Regul Syst Bio. 2016. PMID: 27429547 Free PMC article.
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ. Gonzalez EE, et al. Among authors: lacave aj. Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13. Invest New Drugs. 2011. PMID: 20464446 Clinical Trial.
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ. Crespo G, et al. Among authors: lacave aj. Int J Gynecol Cancer. 2011 Apr;21(3):478-85. doi: 10.1097/IGC.0b013e31820d738c. Int J Gynecol Cancer. 2011. PMID: 21436695 Clinical Trial.
70 results